文献速递垂体与肾上腺疾病

靶向11β-羟化酶用[131I]IMAZA治疗晚期肾上腺皮质癌的新方法

Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

本研究采用诊断性[123I]IMAZA扫描筛查69例不可切除转移性肾上腺皮质癌患者,其中13例接受中位25.7 GBq [131I]IMAZA治疗。2例RECIST靶病灶缩小26%,5例疾病稳定者中位无进展生存14.3个月,全部患者中位总生存14.1个月,未观察到CTCAE≥3级严重毒性。

要点

  • 69例晚期肾上腺皮质癌中38.5%肿瘤病灶显示高[131I]IMAZA摄取。
  • 13例接受[131I]IMAZA治疗,2例靶病灶缩小26%,5例疾病稳定。
  • 疾病稳定者中位无进展生存14.3个月,全部患者中位总生存14.1个月。

核心结论

  • 在标准治疗方案难治的晚期肾上腺皮质癌患者中,[131I]IMAZA治疗与疾病稳定及部分患者非显著性肿瘤缩小相关,且毒性有限。
  • 38.5%的晚期肾上腺皮质癌患者肿瘤病灶显示高[131I]IMAZA摄取,使[131I]IMAZA成为限于明确界定患者亚群的潜在治疗选择。
  • 需要进一步临床试验评估这种新型诊疗方法的全部潜力。

研究设计与样本

  • 研究对69例不可切除转移性肾上腺皮质癌患者使用诊断性[123I]IMAZA扫描进行筛查。
  • 所有肿瘤病灶均显示显著摄取的患者接受[131I]IMAZA治疗。
  • 肿瘤反应按RECIST 1.1版评估,不良反应按常见毒性标准5.0版评估。

主要发现

  • 筛查后13例患者接受治疗,中位剂量25.7 GBq [131I]IMAZA(范围18.1-30.7 GBq),其中5例接受第二疗程治疗。
  • 最佳反应为2例患者RECIST靶病灶缩小26%。
  • 5例疾病稳定患者的中位无进展生存期为14.3个月(范围8.3-21.9)。
  • 全部患者治疗后的中位总生存期为14.1个月(范围4.0-56.5)。
  • 治疗耐受良好,未观察到CTCAE≥3级严重毒性。

局限性

  • 需要进一步临床试验评估这种新型诊疗方法的全部潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with limited treatment options. Theranostic approaches with adrenal specific radiotracers hold promise for improved diagnostics and treatment. OBJECTIVE: Here, we report a new theranostic approach to advanced ACC applying (R)-1-[1-(4-[123I]iodophenyl)ethyl]-1H-imidazole-5-carboxylic acid azetidinyl amide ([123I]IMAZA) for diagnostic imaging and [131I]IMAZA for radionuclide therapy. METHODS: Sixty-nine patients with nonresectable, metastatic ACCs were screened using a diagnostic [123I]IMAZA scan. Patients with significant uptake in all tumoral lesions were offered treatment with [131I]IMAZA. Tumor response was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST version 1.1), and adverse effects were assessed by Common Toxicity Criteria (version 5.0). RESULTS: After screening, 13 patients were treated with a median of 25.7 GBq [131I]IMAZA (range 18.1-30.7 GBq). Five individuals received a second treatment course. Best response was a decrease in the RECIST target lesions of -26% in 2 patients. Five patients with disease stabilization experienced a median progression-free survival of 14.3 months (range 8.3-21.9). Median overall survival in all patients was 14.1 months (4.0-56.5) after therapy. Treatment was well tolerated, in other words no severe toxicities (CTCAE grade ≥3) were observed. CONCLUSION: In patients with advanced ACC refractory to standard therapeutic regimens, [131I]IMAZA treatment was associated with disease stabilization and nonsignificant tumor size reduction in a significant patient fraction and only limited toxicities. High [131I]IMAZA-uptake in tumor lesions was observed in 38.5% of patients with advanced ACC, rendering [131I] IMAZA a potential treatment option in a limited, well-defined patient fraction. Further clinical trials will be necessary to evaluate the full potential of this novel theranostic approach.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Hahner S, Hartrampf PE, Mihatsch PW, et al. Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2022. PMID: 34904171. doi:10.1210/clinem/dgab895

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。